Neuronetics, Inc.
NASDAQ:STIMMedical - Diagnostics & Research
+$0.00 today
- Market cap
- $97.16M
- Beta
- 1.04
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.53
Volume 2.55M
Average 2.44M
STIM Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Neuronetics, Inc.NASDAQ: STIM
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $559K, compared with -$2.64M a year earlier. Trailing-twelve-month accounts payables was $1.45M. Over 3 fiscal years it compounded at -3.8% a year.
Context
- Accounts payables amounted to 1.2% of revenue in FY2025, down 1.5 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $559K or moves back toward the trailing-twelve-month quarterly average of $361.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.75M) USD
- Year-over-year change
- +11.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.75M) | +11.8% |
| FY2024 | 2024-12-31 | (1.99M) | -197.8% |
| FY2023 | 2023-12-31 | 2.03M | +203.1% |
| FY2022 | 2022-12-31 | (1.97M) | -813.0% |
| FY2021 | 2021-12-31 | 276K | — |
Accounts Payables vs competitors
How STIM compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +154.8% is the 2nd highest of 8, against a peer median of -23.4%.
- Accounts payables amounts to 1.0% of revenue for STIM, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.73M USD | — | — | 3.3% | |
| LTM Mar 2026 | $3.51M USD | +170.1% | -40.6% | 10.2% | |
| LTM Mar 2026 | $3.11M USD | +137.8% | — | 2.8% | |
| LTM Mar 2026 | $3.04M USD | -297.9% | — | 3.9% | |
| LTM Mar 2026 | €2.84M EUR | — | — | 17.4% | |
| LTM Mar 2026 | $2.36M USD | -321.8% | — | 381.1% | |
| LTM Mar 2026 | $1.45M USD | +154.8% | -3.8% | 1.0% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $941.09K USD | -23.4% | — | 0.2% |
| LTM Mar 2026 | $387.3K USD | -77.1% | — | 2.1% | |
| LTM Mar 2026 | $215K USD | +111.0% | — | 0.7% | |
| Peer median (excluding STIM) | — | -23.4% | -40.6% | 3.3% | |
Competitors are the stored peer set for STIM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.19M) | (37.16M) | (30.19M) | (43.73M) | (39.14M) |
| Depreciation & Amortization | 1.06M | 1.65M | 2.01M | 2.07M | 3.47M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.87M | 8.75M | 7.32M | 5.6M | 6.85M |
| Change in Working Capital | (6.64M) | (5.12M) | (14.1M) | (6.81M) | 6.58M |
| Accounts Receivables | (3.05M) | (6.66M) | (8.83M) | (3.73M) | 3.54M |
| Inventory | (3.44M) | (2.59M) | (1.1M) | 3.15M | (395K) |
| Accounts Payables | 276K | (1.97M) | 2.03M | (1.99M) | (1.75M) |
| Other Working Capital | (415K) | 6.1M | (6.2M) | (4.25M) | 5.18M |
| Other Non-Cash Items | 918K | 1.14M | 2.93M | 11.86M | 1.87M |
| Operating Cash Flow | (27.98M) | (30.74M) | (32.04M) | (31M) | (20.37M) |
| Capital Expenditures | (2.35M) | (3.27M) | (2.37M) | (1.47M) | (801K) |
| Acquisitions (Net) | 0 | 0 | 0 | (2.55M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 324K | 0 | 0 | 0 | (31K) |
| Other Investing Activities | (7.81M) | 10M | 1.05M | 1.61M | 31K |
| Investing Cash Flow | (9.84M) | 6.73M | (1.32M) | (2.41M) | (801K) |
| Debt Repayment | 0 | 0 | 23.8M | (2.52M) | 9.62M |
| Common Stock Issued | 80.97M | 0 | 0 | 0 | 26.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.03M | 207K | (1.1M) | (4.29M) | (594K) |
| Financing Cash Flow | 83.01M | 207K | 22.7M | (6.81M) | 35.85M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.18M | (23.8M) | (10.66M) | (40.22M) | 14.68M |
| Free Cash Flow | (30.34M) | (34.01M) | (34.41M) | (32.46M) | (21.18M) |
Neuronetics, Inc.
NASDAQ:STIM
Intrinsic Alpha fair value
Locked
Current Price
$1.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.